CONCLUSIONS Recent investigations have elucidated a multifaceted spectrum of adverse effects linked to GLP-1 RAs (Table 1), necessitating meticulous interpretation based on the various methodological designs employed, including RCTs and retrospective analyses
In vitro, GLP-1(936) (30 pmol/l) alone did not increase insulin secretion when tested at either glucose concentration
What is less obvious is the extent to which changing consumption patterns by users will impact traditional food categories particularly snack foods
Most employer health plans dont cover new blockbuster weight loss drugs, but thats going to change
If insomnia is affecting your quality of life, your provider may adjust the dose, timing, or recommend supportive strategies
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus